Invention Grant
- Patent Title: Methods of treatment using CTLA4 mutant molecules
-
Application No.: US15668824Application Date: 2017-08-04
-
Publication No.: US10370428B2Publication Date: 2019-08-06
- Inventor: Robert James Peach , Joseph Naemura , Peter S. Linsley , Jurgen Bajorath
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agent Nickki L. Parlet
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K38/17 ; C07K14/725 ; C07H21/04 ; C12N5/0783 ; A61K39/395 ; A61K39/39 ; A61K38/00 ; A61K39/00
Abstract:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Public/Granted literature
- US20180134764A9 METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES Public/Granted day:2018-05-17
Information query
